Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global Industry Hails Bioequivalence Progress

ICH Working Group Starts Devising Plan

Executive Summary

For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.

You may also be interested in...



Sboul Is Appointed IGBA Chair

Hanan Sboul, secretary general of the Jordanian Association of Pharmaceutical Manufacturers, has been named as chair of the International Generic and Biosimilar medicines Association. She takes over from Jim Keon, president of the Canadian Generic Pharmaceutical Association.

ICH Sets Out Proposals On Harmonizing Standards For Generics

The ICH has published a reflection paper on harmonizing technical and scientific standards for generics that envisages initially developing guidelines on bioequivalence standards for non-complex oral dosage forms, followed by guidance on more complex dosage forms or products. A discussion group will also be established to identify opportunities to include generics in other ICH guidelines.

Joining ICH committee is ‘milestone’ for IGBA

Global generics and biosimilars industry representatives have celebrated a “historical moment for our industry” after the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) elected the International Generic and Biosimilar Medicines Association (IGBA) as a member of its management committee.

Topics

UsernamePublicRestriction

Register

GB149431

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel